Table 1 Patient characteristics of the whole cohort at baseline sample collection (n=109) according to obesity status
From: The association between obesity and weight loss after bariatric surgery on the vaginal microbiota
Characteristics | Non-obese (n=67) | Obese (n=42) | Total (n=109) | p valuea |
|---|---|---|---|---|
Age (years) | Â | Â | Â | 0.083 |
 Mean (SD, range) | 44 (11.79, 20-75) | 46 (11.26, 28-72) | 44 (11.79, 20-75) |  |
Ethnicity, n/N (%) | Â | Â | Â | 0.024 |
 Caucasian | 48/67 (71.6) | 22/42 (52.4) | 70/109 (64.2) |  |
 Asian | 3/67 (4.5) | 5/42 (11.9) | 8/109 (7.3) |  |
 Black | 12/67 (17.9) | 15/42 (35.7) | 27/109 (24.8) |  |
 Other | 4/67 (6.0) | 0/42 (0) | 4/109 (3.7) |  |
Parity, n/N (%) | Â | Â | Â | <0.001 |
 Nulliparous | 44/67 (65.7) | 7/42 (16.7) | 51/109 (46.8) |  |
 Parous | 23/67 (34.3) | 35/42 (83.3) | 58/109 (53.2) |  |
Smoking status, n/N (%) | Â | Â | Â | 0.128 |
 Current smoker | 11/67 (16.4) | 2/42 (4.8) | 13/109 (11.9) |  |
 Non-smoker | 56/67 (83.6) | 40/42 (95.2) | 96/109 (88.1) |  |
HVS results n/N (%) | Â | Â | Â | 0.062 |
 Normal | 46/67 (68.7) | 36/42 (85.7) | 82/109 (75.2) |  |
 Abnormal | 15/67 (22.4) | 6/42 (14.3) | 21/109 (19.3) |  |
 Unknown | 6/67 (8.9) | 0/42 (0) | 6/109 (5.5) |  |
Abnormal HVS results, n/N (%) | Â | Â | Â | 0.076 |
 Bacterial vaginosis | 3/15 (20.0) | 1/6 (16.7) | 4/21 (19.0) |  |
 E. coli | 1/15 (6.7) | 0/6 (0) | 1/21 (4.8) |  |
 S. aureus | 1/15 (6.7) | 0/6 (0) | 1/21 (4.8) |  |
 Group B streptococcus (S. agalactiae) | 2/15 (13.3) | 3/6 (50.0) | 5/21 (23.8) |  |
 Yeast | 0/15 (0) | 1/6 (16.7) | 1/21 (4.8) |  |
 Mixed coliforms | 0/15 (0) | 1/6 (16.6) | 1/21 (4.8) |  |
 Unknown | 8/15 (53.3) | 0/6 (0) | 8/21 (38.0) |  |
Menopause status, n/N (%) | Â | Â | Â | 0.233 |
 Premenopausal | 50/67 (74.6) | 26/42 (61.9) | 76/109 (70.0) |  |
 Postmenopausal | 17/67 (25.4) | 16/42 (38.1) | 33/109 (30.0) |  |
Phase of menstrual cycle (PrMP), n/N (%) | Â | Â | 0.115 | |
 Luteal | 24/50 (48.0) | 7/26 (26.9) | 31/76 (40.8) |  |
 Follicular | 15/50 (30.0) | 8/26 (30.8) | 23/76 (30.3) |  |
 Ovulation | 0/50 (0) | 1/26 (3.8) | 1/76 (1.3) |  |
 Unknown | 11/50 (22.0) | 10/26 (38.5) | 21/76 (27.6) |  |
Use of contraception (PrMP), n/N (%) | Â | Â | Â | 0.016 |
 Nil | 27/50 (54.0) | 20/26 (77.0) | 47/76 (61.9) |  |
 Condoms | 5/50 (10.0) | 0/26 (0) | 5/76 (6.6) |  |
 COCP | 12/50 (24.0) | 1/26 (3.8) | 13/76 (17.1) |  |
 POP | 1/50 (2.0) | 0/26 (0) | 1/76 (1.3) |  |
 Copper IUD | 0/50 (0) | 0/26 (0) | 0/76 (0) |  |
 Mirena IUS | 3/50 (6.0) | 5/26 (19.2) | 8/76 (10.5) |  |
 Vaginal ring | 0/50 (0) | 0/26 (0) | 0/76 (0) |  |
 Contraceptive implant | 2/50 (4.0) | 0/26 (0) | 2/76 (2.6) |  |
 Contraceptive injection | 0/50 (0) | 0/26 (0) | 0/76 (0) |  |
Use of HRT (PoMP), n/N (%) | Â | Â | Â | 0.175 |
 Yes | 5/17 (29.4) | 1/16 (6.2) | 6/33 (18.2) |  |
 No | 12/17 (70.6) | 15/16 (93.8) | 27/33 (81.8) |  |
Diabetes status, n/N (%) | Â | Â | Â | 0.001 |
 Non-diabetic | 65/67 (97.0) | 32/42 (76.2) | 97/109 (89.0) |  |
 Diabetic | 2/67 (3.0) | 10/42 (23.8) | 12/109 (11.0) |  |
Diabetic treatment, n/N (%) | Â | Â | Â | 0.212 |
 Diet control only | 1/2 (50.0) | 3/10 (30.0) | 4/12 (33.3) |  |
 Metformin alone | 0/2 (0) | 3/10 (30.0) | 3/12 (25.0) |  |
 Metformin combined 2nd diabetic medication | 0/2 (0) | 0/10 (0) | 0/12 (0) |  |
 Other oral antiglycaemic medication | 1/2 (50.0) | 0/10 (0) | 1/12 (8.4) |  |
 Insulin (alone or with oral medication) | 0/2 (0) | 4/10 (40.0) | 4/12 (33.3) |  |
HOMA-IRb, n/N (%) | Â | Â | Â | 0.136 |
 Insulin resistant | 2/67 (3.0) | 5/42 (11.9) | 7/109 (6.4) |  |
 Non-insulin resistant | 5/67 (7.5) | 5/42 (11.9) | 10/109 (9.2) |  |
 Unknown insulin resistance status | 60/67 (89.5) | 32/42 (76.2) | 92/109 (84.4) |  |